cbdMD, Inc.

As of February 9, 2021, cbdMD, Inc. is considered overvalued with a deteriorating outlook, reflected in its high Price to Book Value of 8.51, negative financial metrics including a P/E ratio of -3.7225, and a significant year-to-date stock decline of -76.01% compared to the S&P 500's 12.22% return.

As of February 9, 2021, cbdMD, Inc. has been downgraded to a risky valuation grade due to being overvalued with negative performance metrics, including a Price to Book Value of 8.51, an EV to EBITDA of 7.49, a ROE of -119.47%, and a year-to-date stock decline of 72.47% compared to the S&P 500's gain of 2.44%.

As of June 11, 2025, the technical outlook has shifted to bearish, supported by bearish daily moving averages and KST indicators, despite a mildly bullish MACD, with overall sentiment weakened by Bollinger Bands and underperformance against the S&P 500.

cbdMD, Inc. specializes in consumer hemp-based cannabidiol (CBD) products within the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $5 million and has a market cap of $7.32 million.

As of Jun 18, cbdMD, Inc. has a market capitalization of 7.32 million, with net sales of 19.59 million and a net profit of -0.15 million over the last four quarters. As of September 2024, the company reported shareholder's funds of 1.96 million and total assets of 10.58 million.